Neurology;Neurologie

Revue Medicale Suisse

Volumn 1, Issue 1, 2005, Pages 44-50

  Carrera, Emmanuel ^a   Bogousslavsky, Julien ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

BLOOD CLOT LYSIS; BRAIN DEPTH STIMULATION; CEREBROVASCULAR ACCIDENT; GENE TARGETING; MEDICAL PRACTICE; MYOPATHY; NEUROLOGIC DISEASE; PARKINSON DISEASE; REVIEW; BRAIN DISEASE; CEREBROVASCULAR DISEASE; HUMAN; MULTIPLE SCLEROSIS; NEUROMUSCULAR DISEASE; PRACTICE GUIDELINE;

BRAIN DISEASES; CEREBROVASCULAR DISORDERS; HUMANS; MULTIPLE SCLEROSIS; NEUROMUSCULAR DISEASES; PARKINSON DISEASE; PRACTICE GUIDELINES;

EID: 21844461890     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Eng J Med 1995; 333: 1581-7.
2. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-11.
3. Burton A. Abciximab extends treatment window for stroke. Lancet Neurol 2003; 2: 390.
4. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-74.
5. Muir KW, Lees KR, Ford I, et al. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): Randomised controlled trial. Lancet 2004; 363: 439-45.
6. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967-75.
7. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
9. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
10. Olsson SB; Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 2003; 362: 1691-8.
11. Albers GW. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF V). Am Acad Neurol 2004; plenary session.
12. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
13. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363: 915-24.
14. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: Randomised controlled trial. Lancet 2004; 363: 1491-502.
15. Fahn S. Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the ELLOOPA trial. Neurology 2003; 60 (Suppl. 1): A80-A1.
16. Groupe de travail de la commission de thérapie de la Société suisse de neurologie (SSN). Recommandations pour le traitement de la maladie de Parkinson. Schweizer Archiv für Neurologie und Psychiatrie 2004; 155: 74-8.
17. Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004; 62: S64-S71.
18. Pritschett AM, Morrisson JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002; 77: 1280-6.
19. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-83.
20. Baseman DG, O'Suilleabhain PE, Reimold SC, et al. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63: 301-4.
21. Paus S, Brecht HM, Köster J, et al. Sleep attacks, daytime sleepines and dopamine agonists in Parkinson's disease. Mov Dis 2003; 18: 659-67.
22. Russmann H, Ghika J, Combrement P, et al. L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction. Neurology 2004; 63: 153-5.
23. Vingerhoets FJ, Villemure JG, Temperli P, et al. Subthalamic DBS replaces levodopa in Parkinson's disease: Two-year follow-up. Neurology 2002; 58: 396-401.
24. Krack P, Batir A, Van Belcorm N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925-34.
25. Burkhard P, Vingerhoets FJ, Bogousslavsky J, et al. Suicides in successful DBS for movement disorders. Neurology 2004; (in press).
26. Kappos L, Beer K, Beer S, Schluep M, Vaney C. Indications des médicaments immunomodulateurs dans le traitement de la sclérose en plaque (SEP) 2004.
27. Barbero P, Verdun E, Bergui M, et al. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: The interferon beta dose-reduction study. Neurol Sci 2004; 222: 13-9.
28. Rio J, Nos C, Bonaventura I, et al. Corticosteroids, ibuprofen, and acetaminophen for INFb-1a flu syndroms in MS: A randomized trial. Neurology 2004; 63: 525-8.
29. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis. Lancet 2002; 360: 2018-25.
30. Miller DH, Khan OA, Sheremata WA, et al. International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
31. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses. Neurology 2004; 64: 2038-43.
32. Hohlefeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines. PNAS 2004; 202: 14599-606.
33. Frohman EM, Brannon K, Racke MK, et al. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004; 27: 80-3.
34. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon b. Proc Natl Acad Sci USA 2004; 101: 8705-8.
35. Pender MP. The pathogenesis of primary progressive multiple sclerosis: Antibody-mediated attack and no repair? J Clin Neurosci 2004; 11: 689-92.
36. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs 1: Treatment of new onset epilepsy. Neurology 2004; 62: 1252-60.
37. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial: Oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204.
38. Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbamazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6.
39. Christie W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 451-60.
40. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-75.
41. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476-9.
42. Steiner TJ, Dellaportas CL, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy. A double-blind comparison with phenytoin. Epilepsia 1999; 40: 601-7.
43. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizure: Results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42.
44. Pradeep Kumar A, Smith PEM. Levetiracetam as addon therapy in generalised epilepsies. Seizure 2004; 13: 468-70.
45. Sabers A, Dam M, a-Rogvi-Hansen B, et al. Epilepsy and pregnancy: Lamotrigine as main drug used. Acta Neurol Scand 2004; 109: 9-13.
46. Rossetti A, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: A study of 31 episodes. Epilepsia 2004; 45: 757-64.
47. Cummings JL. Alzheimer's disease. N Eng J Med 2004; 351: 56-67.
48. Ritchie CW, Ames D, Clayton T. Metaanalysis of randomized trials of the efficacy and safely of donepezil, galantamine and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr psychiatry 2004; 12: 358-69.
49. Salloway S, Ferris S, Kluger A, et al. for the Donepezil «401» study Group. Efficacy of donepezil in mild cognitive impairment Neurology 2004; 63: 651-7.
50. Reisberg B, Doody R, Stöffler A, et al. for the memantine study Group. Memantine in moderate-to-severe Alzheimer's disease. N Eng J Med 2003; 348: 1333-41.
51. Tarrot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004; 291: 317-24.
52. Masse I, Bordet R, Deplanque D, et al. Effects of statins and fibrates on progression of cognitive decline in Alzheimer disease. Am Acad Neurol 2004; 103 (Suppl.) S17. Abstract.
53. Siemers ER, Quinn JL, Kaye J, et al. Effect of LY450139, a functional g-secretase inhibitor on plasma and cerebrospinal fluid concentrations of Ab and cognitive functioning in patients with mild to moderate Alzheimer. Am Acad Neurol 2004; 101 (Suppl.) S17. Abstract
54. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54.
55. Ekinjuntti T, Román G, Gauthier S, et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004; 35: 1010-7.
56. Silberstein SD. Migraine. Lancet 2004; 363: 281-91.
57. Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003; 43: 214-22.
58. Sterner TJ, Diener HC, MacGregor EA, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalagia 2003; 23: 942-52.
59. Ahonen K, Hämäläinen ML, Rentala H, et al. Nasal sumatriptan is effective in treatment of migraine attacks in children. Neurology 2004; 62: 883-7.
60. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention. JAMA 2004; 291: 965-73.
61. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA 2003; 289: 65-9.
62. Diener HC. Advances in the field of headache 2003/2004. Curr Opin Neurol 2004; 17: 271-3.
63. Diener HC, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis. Results from a placebo-controlled trial with propanolol as an active control. J Neurol 2004; 251: 943-50.
64. Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin 2001; 19: 829-47.
65. Kuntzer T. La sclérose latérale amyotrophique: une maladie progressive des neurones moteurs et de la microglie. Schweiz Archives of Neurology and Psychiatry 2003; 154: 76-80.
66. Ryberg H, Askmark H, Persson LI. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: Effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 2003; 108: 1-8.
67. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437-45.
68. Dalakas MC. Understanding the immunopathogenesis of inclusion-body myositis: Present and future prospects. Rev Neurol (Paris) 2002; 158: 948-58.
69. Mastaglia FL, Garlepp MJ, Philips BA, et al. Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003; 27: 407-25.
70. Dalakas MC. Inflammatory disorders of muscle: Progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004; 17: 561-7.
71. Kuntzer T, Lobrinus A. Parésie indolore progressive et segmentaire de l'adulte; myosites à inclusions. La lettre du neurologue 2004; hors série; 64.
72. Rowin J, Merrigioli MN, Tuzun E, et al. A pilot trial of etanercept in the treatment of steroid-dependant, generalized autoimmune myasthenia gravis. Neurology 2004; 62(Suppl. 5): A185.
73. Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: Immunotherapy for Guillain-Barré syndrome: Report of the quality standards. Subcomitee of the American Academy of Neurology. Neurology 2003; 61: 736-40.
74. van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: Randomised trial. Lancet 2004; 363: 192-6.
75. Corson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004; 63: 715-7.
76. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10: 396-401.
77. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2004: CD003725.
78. Williams MS. Myostatin mutation associated with gross muscle hypertrophy in a child. N Eng J Med 2004; 350: 2682-8.